These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30001427)

  • 41. Burden of disease and cost of chronic hepatitis C infection in Canada.
    Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
    Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Type 2 diabetes mellitus, insulin resistance and hepatocellular carcinoma in chronic hepatitis C patients.
    Lombay B; Szilágyi R; Szalay F
    Orv Hetil; 2019 Oct; 160(40):1591-1602. PubMed ID: 31565976
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
    Polaris Observatory HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):161-176. PubMed ID: 28404132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States.
    Reid AE; Koziel MJ; Aiza I; Jeffers L; Reddy R; Schiff E; Lau JY; Dienstag JL; Liang TJ
    Am J Gastroenterol; 1999 Jun; 94(6):1619-26. PubMed ID: 10364034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
    Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
    CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HCV genotypes and age distribution in patients of Vienna and surrounding areas.
    Haushofer AC; Kopty C; Hauer R; Brunner H; Halbmayer WM
    J Clin Virol; 2001 Jan; 20(1-2):41-7. PubMed ID: 11163582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
    Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
    J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    Am J Gastroenterol; 2014 Sep; 109(9):1427-35. PubMed ID: 25070058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.
    Kileng H; Bernfort L; Gutteberg T; Moen OS; Kristiansen MG; Paulssen EJ; Berg LK; Florholmen J; Goll R
    BMC Infect Dis; 2017 Sep; 17(1):624. PubMed ID: 28915795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
    Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
    Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030.
    Meijerink H; White RA; Løvlie A; de Blasio BF; Dalgard O; Amundsen EJ; Melum E; Kløvstad H
    BMC Infect Dis; 2017 Aug; 17(1):541. PubMed ID: 28774261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France.
    Larsen C; Bousquet V; Delarocque-Astagneau E; Pioche C; Roudot-Thoraval F; ; ; Desenclos JC
    J Med Virol; 2010 Oct; 82(10):1647-54. PubMed ID: 20827760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High prevalence of antibodies to core+1/ARF protein in HCV-infected patients with advanced cirrhosis.
    Kassela K; Karakasiliotis I; Charpantidis S; Koskinas J; Mylopoulou T; Mimidis K; Sarrazin C; Grammatikos G; Mavromara P
    J Gen Virol; 2017 Jul; 98(7):1713-1719. PubMed ID: 28708052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of SEN virus on immunoblot INNO-LIA HCV reactivity pattern and disease outcome in Egyptian hepatocellular carcinoma patients.
    Alam El-Din HM; Abo-Shadi MA; Helal A
    Egypt J Immunol; 2007; 14(1):1-10. PubMed ID: 18689276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heading Toward the Elimination of Hepatitis C Virus.
    Kershenobich D; Torre-Delgadillo A; Aguilar-Valenzuela LM
    Rev Invest Clin; 2018; 70(1):29-31. PubMed ID: 29513300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    Tergast TL; Blach S; Tacke F; Berg T; Cornberg M; Kautz A; Manns M; Razavi H; Sarrazin C; Serfert Y; van Thiel I; Zeuzem S; Wedemeyer H
    J Viral Hepat; 2022 Jul; 29(7):536-542. PubMed ID: 35357770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prevalence of hepatitis C virus types in patients of the same geographic area, according to the source of infection and liver disease.
    Sacco R; Randone A; Flichman D; Oliveri F; Colombatto P; Scaraggi FA; Bonino F; Schiraldi O; Brunetto MR
    Clin Diagn Virol; 1997 Nov; 8(3):189-94. PubMed ID: 9406648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.